echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Focus on tumor prevention and control, experts call for: early screening, early diagnosis and early treatment of liver cancer should be concerned by the whole society

    Focus on tumor prevention and control, experts call for: early screening, early diagnosis and early treatment of liver cancer should be concerned by the whole society

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    "The early prevention, early screening, early diagnosis, and early treatment of tumors are not only the tasks of scientists, but also things that the whole society should pay attention to.
    " Wang Hongyang, academician of the Chinese Academy of Engineering and director of the National Liver Cancer Science Center, pointed out.

    On April 17, sponsored by Eastern Hepatobiliary Surgery Hospital of Naval Military Medical University/National Liver Cancer Science Center, co-organized by Fujian Cancer Hospital and Mengchao Hepatobiliary Hospital of Fujian Medical University, undertook by Herui Gene, supported by People’s Daily Health Client and Chief Media of Health Times The National Multi-center Prospective Liver Cancer Very Early Warning Screening Project (PreCar) Progress Meeting and the First Tumor Early Diagnosis and Treatment Precision Prevention and Control Summit Forum was held in Fuzhou.
    Academician Wang Hongyang shared at the meeting, "I am returning from studying in Germany.
    Since then, I have been appealing, hoping to strengthen the early screening and diagnosis of malignant tumors, and not to concentrate all our energy on the treatment of mid- to late-stage tumors.
    Although the treatment of these patients is also a very important task for us, we should prevent more patients from suffering The transformation of chronic inflammation into malignant diseases and blocking the process of inflammatory cancer transformation is the most effective way for us to deal with the challenge.
    "


    Academician of the Chinese Academy of Engineering, Director of the National Liver Cancer Science Center Wang Hongyang Academician of the Chinese Academy of Engineering, Director of the National Liver Cancer Science Center Wang Hongyang Academician of the Chinese Academy of Engineering, Director of the National Liver Cancer Science Center Wang Hongyang

    Promote early screening, diagnosis and treatment of liver cancer

    Promote early screening, diagnosis and treatment of liver cancer

    Blocking the transformation process of inflammatory cancer is the most effective way to prevent and treat tumors

    Blocking the transformation process of inflammatory cancer is the most effective way to prevent and treat tumors

    In recent years, the incidence and mortality of cancer in my country have both been on the rise.


    Take liver cancer as an example.


    At the meeting, Professor Hou Jinlin, director of the Department of Infectious Medicine, Nanfang Hospital of Southern Medical University, proposed a "pyramid" strategy for liver cancer screening.


    Has a sensitivity of 95.


    Has a sensitivity of 95.


    PreCar project helps "lock in" liver cancer in advance

    In 2018, led by Academician Wang Hongyang from Eastern Hepatobiliary Surgery Hospital of Naval Military Medical University/National Liver Cancer Science Center, and Professor Hou Jinlin from Southern Hospital of Southern Medical University, Herui Gene led the implementation of a prospective clinical project for early screening of liver cancer with the participation of nearly 20 domestic clinical centers.


    In February this year, the international journal Cell Research published the first clinical research results based on the PreCar project.


    "The two-wheel drive of'scientific research + clinical practice', exploring and solving all the pain points of screening, diagnosis, treatment and prognosis" is the follow-up plan and goal of Herui Gene.


    Among them, primary liver cancer is one of the common malignant tumors in my country, and its onset is closely related to liver cirrhosis.


    At the same time, at the meeting, the project team announced new trends including "cfDNA-based auxiliary diagnosis of benign and malignant liver cirrhotic nodules" and "live and postoperative cfDNA dynamic monitoring of liver cancer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.